In addition to the adverse prognostic impact of homozygous deletions of CDKN2A/B in astrocytomas as acknowledged in the current WHO 2021 classification [2], also an association of hemizygous deletions has been described recently [25]. The gene discussed is CDKN2A; the disease is astrocytoma (excluding glioblastoma).